Table 3.

Prospective studies in adolescents and young adults with acute lymphoblastic leukemia treated with pediatric-based or-inspired protocols.

Country (reference)	Protocol	Age	N	CR (%)	EFS (%)
USA (36)	DFCI 91-01, 95-01	15–18*	51*	94	78
Spain (34)	PETHEMA ALL-96	15–18	35	94	60
		19–30	46	100	63
France (31)	GRAALL-2003	15–45	172	95	58
USA (37)	DFCI	18–50	74	82	72.5**
Canada (33)	Modified DFCI	17–71	68	85	65***
France (38)	FRALLE-2000	16–57	30	90	90****
Holland-Belgium(32)	HOVON 70	17–39	54	91	66**

^*Results restricted to adolescents;

^**Estimated at 2 years;

^***Overall survival.

^****Disease-free survival.